J&J push­es new ami­van­tam­ab da­ta for NSCLC sub­set, try­ing to bol­ster case for quick FDA ap­proval

Hav­ing al­ready filed for a quick OK for ami­van­tam­ab in a sub­set of metasta­t­ic non-small cell lung can­cer pa­tients, J&J’s Janssen unit on Thurs­day pre­sent­ed more da­ta at WCLC hop­ing to boost the ex­per­i­men­tal drug’s case.

Re­searchers pro­vid­ed an up­date on a Phase I ami­van­tam­ab co­hort tar­get­ing pa­tients with EGFR ex­on 20 in­ser­tion mu­ta­tions, a lit­tle over a month af­ter pre­sent­ing a small­er amount of da­ta at AS­CO. Though the first EGFR in­hibitors were ap­proved more than a decade ago, the com­pa­ny says its EGFR/MET bis­pe­cif­ic would be the first drug on the mar­ket to treat this spe­cif­ic mu­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER